Estimated gain in life expectancy. A simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction

European Heart Journal

Volumn 17, Issue 1, 1996, Pages 64-75

  Boersma, H ^a   Van der Vlugt, M J ^a   Arnold, A E R ^a   Deckers, J W ^a   Simoons, M L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Decision making; Direct PTCA; Life expectancy; Myocardial infarction; Thrombolysis

Indexed keywords

ALTEPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN HEMORRHAGE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING;

EID: 0029930158     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.eurheartj.a014693     Document Type: Review

References (0)